Literature DB >> 22530578

Recent advances in the treatment of HIV/HBV and HIV/HCV co-infection.

A Masgala1, S Bonovas, G K Nikolopoulos.   

Abstract

Concurrent infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) in patients positive for human immunodeficiency virus (HIV) is relatively common. The treatment of co-infected individuals is rather complex because the anti-viral therapy may be associated with drug-resistance, hepatotoxicity and lack of response. Herein, we present a summary of the available compounds and the recent recommendations concerning the therapeutic management of HIV/HBV and HIV/HCV co-infections.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22530578     DOI: 10.2174/138955712800959062

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  3 in total

Review 1.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

2.  Association Between ABCB1 (MDR1) Gene Polymorphism and Unresponsiveness Combined Therapy in Chronic Hepatitis C virus.

Authors:  Meryem Timucin; Hakan Alagozlu; Semra Ozdemir; Ozturk Ozdemir
Journal:  Hepat Mon       Date:  2013-04-13       Impact factor: 0.660

3.  Computational analysis to predict functional role of hsa-miR-3065-3p as an antiviral therapeutic agent for treatment of triple infections: HCV, HIV-1, and HBV.

Authors:  Ambreen Khokhar; Samina Noorali; Muhammad Sheraz; Kuha Mahalingham; Donald G Pace; Mohammad R Khanani; Omar Bagasra
Journal:  Libyan J Med       Date:  2012-12-31       Impact factor: 1.657

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.